ReviewCureus2023
miRNA Associated With Glucose Transporters in Oral Squamous Cell Carcinoma: A Systematic Review.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Glycolysis-related MiRNA signature predicts prognosis, recurrence risk, and therapeutic responses in hepatocellular carcinoma.Scientific reports · 2025Article
- The role and targeting strategies of non-coding RNAs in immunotherapy resistance in oral squamous cell carcinoma.Frontiers in cell and developmental biology · 2025Review
- Identification of Stage-Specific microRNAs that Govern the Early Stages of Sequential Oral Oncogenesis by Strategically Bridging Human Genetics with Epigenetics and Utilizing an Animal Model.International journal of molecular sciences · 2024Article
- The Association of miRNA10a and Glucose Transporters in Oral Squamous Cell Carcinoma With Diabetes: A Pilot Study.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is a malignancy of the oral cavity with poor prognosis. Dysregulation in glycolytic pathways involving glucose transporters (GLUT) has been implicated in poor prognosis. Furthermore, GLUT expression in cancer cells is regulated by several miRNAs. However, there is a lack of data about miRNA involved in the regulation of GLUT in OSCC. The objective is to evaluate the role of miRNA in the regulation of GLUT in OSCC. Data sources include PubMed (MEDLINE), Scopus, and Web of Science. Studies evaluating the miRNA involved or associated with the regulation of GLUT in OSCC were included in the systematic review. Data pertaining to GLUT and associated miRNA expression were extracted from studies. Qualitative assessment was carried out for GLUT and miRNA. The Newcastle-Ottawa Scale was used for quality assessment. Ten study articles were included after analyzing 4675 papers. These studies evaluated the GLUT and miRNA expression between healthy and OSCC samples. There are variable expression patterns of GLUT in OSCC. Furthermore, it was dependent on miRNA. The GLUT1 and GLUT-3 were detected more frequently in OSCC, while no study reveals the expression of GLUT2, GLUT4, GLUT7, GLUT8, GLUT13, SGLT1, and SGLT2 with miRNA regulation. However, there was insufficient evidence on specific miRNA linked to GLUT1 or GLUT3 expression. There is evidence of the role of miRNA in the regulation of GLUT especially GLUT1 and GLUT3 in OSCC; however, a specific relation to miRNA was understudied. In the future, studies exploring a clearer understanding of the association between miRNA and the GLUT metabolic pathway in relation to OSCC are warranted. Furthermore, association of miRNA and GLUT with progression of disease, disease resistance, and prognosis is assessed for better treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.